Pembrolizumab plus chemotherapy followed by maintenance with or without olaparib as first-line treatment for advanced BRCAwt ovarian cancer with LOH-low: a international cost-effectiveness analysis
In BRCAwt AOC patients with LOH-low, PC is a cost-effective first-line treatment compared to PCO in both the USA and China, particularly among PD-L1 CPS ≥ 10 population.
Authors
- Youwen Zhu (ORCID: https://orcid.org/0000-0001-8692-3591)
- Hong Zhu (ORCID: https://orcid.org/0000-0002-3659-8070)
- Kun Liu (ORCID: https://orcid.org/0000-0001-5807-0501)
- Zhou Xiao-fang (ORCID: https://orcid.org/0009-0001-2205-4785)
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1186/s13048-025-01827-8
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00